Search results
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks via Yahoo Finance· 3 hours agoToday's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel
Marketing Sentinel· 3 days agoCo Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share price was $128.25, and it changed around -$1.81 or -1.39% from the last close, ...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks via Yahoo Finance· 6 days agoBecause of this, empirical studies indicate a strong correlation between trends in earnings estimate...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 5 days agoBut if you pick the right individual stocks, you could make more than that. For example, Merck & Co...
Data-Based Insights About Merck & Co Inc
Stocks Register· 7 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock ...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 1 day agoMerck’s stock has risen 18.6% so far this year compared with an increase of 13.4% for the industry....
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 2 days agoMonday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and...
Robert Bruce's Strategic Moves in Q1 2024: Spotlight on Xcel Energy Inc
GuruFocus.com via Yahoo Finance· 2 days agoThe stock traded at an average price of $64.42 during the quarter, with a 6.99% return over the past...
Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio with Strategic Additions in Q1 2024
GuruFocus.com via Yahoo Finance· 2 days agoThe stock traded at an average price of $42.20 during the quarter and has returned 6.48% over the...
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com· 5 hours agoSpyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of...
